KR20190024566A - Composition for sterilization using synergistic antimicrobial effect of thiamine dilaurylsulfate and medium chain fatty acid - Google Patents

Abstract

The present invention relates to a composition for sterilization using a synergistic antibacterial effect by combination treatment of vitamin B_1 thiamine dilaurylsulfate and a heavy chain fatty acid. The composition for sterilization according to the present invention is harmless to the human body because of not toxicity, prevents deterioration of sensory characteristics of a food generated when the vitamin B_1 thiamine dilaurylsulfate and the heavy chain fatty acid are treated alone, and secures an excellent sterilizing power in a range lower than conventional condition because the synergistic antibacterial effect having a more enhanced antibacterial effect by the combination treatment of the vitamin B_1 thiamine dilaurylsulfate and the heavy chain fatty acid is exhibited. In addition, the composition for sterilization according to the present invention has an advantage of enhancing nutrition by adding the same to various foods.

Description

TECHNICAL FIELD The present invention relates to a composition for sterilization using a synergistic antimicrobial effect of thiamine dilaurylsulfate and medium chain fatty acid,

The present invention relates to a composition for sterilization using a synergistic antibacterial effect by a combination treatment of vitamin B lauryl sulfate and a heavy chain fatty acid.

A bactericide generally means a drug that inhibits or eliminates the growth of microorganisms and bacteria, and is used in various fields such as humidifiers, foods, medical instruments, algae elimination and swimming pools. In particular, as the interest in hygiene and health has increased, the use field of fungicide has been gradually expanded, and various studies are being conducted to develop a fungicide harmless to human body. Since the sterilizing agent is very strong in sterilizing power and antibacterial power, it is generally used to sterilize the sterilizing agent after mixing the sterilizing agent with purified water and a specific solution at a specific concentration required for sterilization. For example, a lactus (chlorine disinfectant) It is used after diluting lactose in water to a specific concentration.

Conventional disinfectants have strong sterilization and lyophilization properties, and therefore, chloromethyl isothiazoline / methyl isothiazolinone (CMIT / MIT: Chloromethyliso-thiazolinone / Methylisothiazolinone) such as a humidifier detergent and a slime detergent and disinfectants known as general disinfectants Recently, PHMG (polyhexamethylene guanidine) and PGH (oligo (2- (2-ethoxy) ethoxyethyl guanidine chloride) have been used as the raw materials of humidifier cleaning agents, have. However, PHMG (polyhexamethylene guanidine) and PGH (oligo (2- (2-ethoxy) ethoxyethyl guanidine chloride) have the advantage of not only having no odor but also being excellent in sterilization and antibacterial effect. However, The toxic component becomes remarkably large as time goes by, causing a problem of damaging the lung. In addition, chlorine-based disinfectants used as general-purpose disinfectants, especially sodium hypochlorite, high-grade whitening calcium hypochlorite, trichloroisocyanuric acid (TCCA), dichloroisocyanuric acid Sodium Dichloroisocyanurate has been used in various fields due to its excellent sterilizing power and antibacterial ability at a price. However, it has been reported that trihalomethane, which is a halogen chemical component including chlorine (Cl) When chlorine is contacted with the human body, chlorine is mixed with the waste products of the human body to generate carcinogenic substance called chloramine. When it comes into contact with the apparatus, it has high oxidation rate to corrode the apparatus, stimulates the ocular mucosa due to its unique strong chlorine odor , And gives unpleasant feeling.

Consumers' anxiety about the above problems is increasing, and development of a sterilizing agent harmless to the human body is required. As an alternative, research on the development of bactericides using natural antimicrobial substances has been carried out, and essential oils extracted from plants and heavy chain fatty acids have been used as representative natural antimicrobial substances. The heavy chain fatty acids present in natural foods such as coconut, palm and coconut are fatty acids composed of 8 to 12 carbon atoms. Examples are caprylic acid (C8), capric acid (C10), lauric acid (lauric acid, C12), each of which has a number of 192, 188 and 180, respectively. In addition to its antibacterial activity, it has been used in food as an antimicrobial agent and nutritional supplements because it has various functions such as body fat decomposition and prevention of metabolic syndrome. Among these, caprylic acid is commonly used in Generally Recognized as Safe (GRAS) And it is recognized as a safe substance even if ingested. However, it has a disadvantage in that it has an undesirable influence on the sensory characteristics of food when it is applied to food due to its inherent flavor. To overcome these disadvantages, it is required to develop a technology that can be used only by using a low concentration which does not affect the sensory characteristics by using other food additives or sterilization techniques.

On the other hand, vitamin B ₁ lauryl sulfate (TDS) is a derivative of vitamin B ₁, which has been developed for enhancing vitamin B ₁ in food. However, since it has been shown that it shows antibacterial activity, it has been approved as a food additive in Korea and Japan and is widely used as a preservative for inhibiting the growth of microorganisms in beverages and sauces. Vitamin B ₁ Lauryl Sulphate is non-toxic and harmless to human body. It is colorless, tasteless, odorless and has no effect on the sensory characteristics of food. However, the solubility in water is low and it is necessary to use ethanol in combination with a high concentration to use it as a liquid preparation. When used in combination with high concentrations of ethanol, there is a concern that the sensory properties of the food may be degraded by ethanol, which may affect the food structure. To overcome these disadvantages, it is necessary to develop a technology that can maximize sterilization power by combining low-concentration vitamin B lauryl sulfate and other food preservatives below the solubility.

Since food safety and quality control are closely related to corporate image and sales, various food companies are investing heavily in developing related technologies. However, they can be easily applied in food companies because of the economic burden due to the development and application of new technologies. Development of a low-cost, high-efficiency process is required. In the food industry, various physico-chemical treatments are performed to ensure microbiological safety, and the nutrient and physico-chemical characteristics of the food can be changed by this treatment, while consumers prefer fresh products that maintain the original form of the food . Therefore, there is a need for a new technology capable of efficiently destroying microorganisms while lowering the intensity of the processes used to develop new technologies or minimizing changes in food. Therefore, economical savings can be expected if a synergistic effect is obtained over a single treatment by combining a treatable substance with a food (see KR10-1567670).

The present inventors have conducted intensive studies to develop a composition for sterilization that does not deteriorate the sensory characteristics of food by analyzing the sterilizing power of bacteria by the treatment of vitamin B lauryl sulphate and heavy chain fatty acid alone or in combination and found that vitamin B lauryl sulphate It was confirmed that the combination of vitamin B lauryl sulphate and medium chain fatty acid in combination with the treatment of the heavy chain fatty acid alone has a synergistic antimicrobial effect that further enhances the antimicrobial effect, and thus the present invention has been completed on the basis thereof.

Accordingly, it is an object of the present invention to provide a composition for sterilization.

However, the technical problem to be solved by the present invention is not limited to the above-mentioned problems, and other matters not mentioned can be clearly understood by those skilled in the art from the following description.

In order to achieve the above object, the present invention provides a composition for sterilization comprising vitamin B lauryl sulfate (TDS) and a medium chain fatty acid as an active ingredient.

In one embodiment of the present invention, the heavy chain fatty acid may be capric acid or caprylic acid.

In another embodiment of the present invention, the vitamin B1 lauryl sulfate may be included in an amount of 0.005 to 0.05 w / v%.

In another embodiment of the present invention, the heavy chain fatty acid may be included at 0.00085-0.02 w / v%.

In another embodiment of the present invention, the capric acid may be included at 0.00085 to 0.004 w / v%, preferably 0.001 to 0.004 w / v%.

In another embodiment of the present invention, the caprylic acid may be included in an amount of 0.005 to 0.02 w / v%.

The composition for sterilization according to the present invention has no toxicity and is harmless to the human body. It prevents the deterioration of the sensory characteristics of foods caused by treatment of vitamin B lauryl sulphate and medium chain fatty acid alone, and the combination of vitamin B lauryl sulfate and heavy chain fatty acid The antimicrobial effect is further enhanced by the synergistic antimicrobial effect, and an advantage of securing an excellent sterilizing power in a range lower than the conditions used in the past.

In addition, the composition for sterilization according to the present invention has an advantage of enhancing nutrition by adding it to various foods.

Fig. 1 shows the results of a microorganism ( E. coli O157: E. coli O157) by treatment with either a control (ethanol 2%), vitamin B lauryl sulfate (0.01, 0.02 w / v%), capric acid (0.1 mM) H7), Salmonella ( Salmonella spp.)).
Fig. 2 shows the results of a microorganism ( E. coli O157: E. coli ) obtained by treatment of a control (ethanol 2%), vitamin B1 lauryl sulfate (0.01, 0.02 w / v%), capric acid (0.2 mM) H7), Salmonella ( Salmonella spp.)).
FIG. 3 is a graph showing the effect of the microorganism ( E. coli O157: E. coli O157) in the control (ethanol 2%), vitamin B1 lauryl sulfate (0.01, 0.02 w / v%), caprylic acid H7), Salmonella ( Salmonella spp.)).
Fig. 4 shows the results of a microorganism ( E. coli O157: E. coli O157: bacterium) by treatment with either a control (ethanol 2%), vitamin B lauryl sulfate (0.01, 0.02 w / v%), caprylic acid H7), Salmonella ( Salmonella spp.)).
FIG. 5 is a graph showing the effect of the combination of vitamin B lauryl sulfate (0.01, 0.02 w / v%) and capric acid (0.1, 0.2 mM) or caprylic acid (0.5, 1.0 mM) Enterococcus faecalis ATCC 19433, Staphylococcus aureus ATCC 6538, Methicillin-resistant Staphylococcus aureus (MRSA) ATCC 33591, Streptococcus pyogenes ATCC 14289, Listeria monocytogenes ATCC 7644, E. coli ATCC 11775, Pseudomonas aeruginosa ATCC 15442, Serratia marcescens ATCC 14756).

The present invention relates to a composition for sterilization exhibiting a synergistic antimicrobial effect in which the antimicrobial effect is further enhanced by a combination treatment of vitamin B lauryl sulfate and a heavy chain fatty acid. Further, it has been found that the composition for sterilization according to the present invention does not deteriorate the food sensory characteristics and has an effect of ensuring an excellent sterilizing power in a range lower than the existing conditions through the synergistic antibacterial effect, and thus it is useful as a disinfectant in various fields You can use it.

Hereinafter, the present invention will be described in detail.

In the present invention, vitamin B lauryl sulphate is a vitamin-B1 derivative having strong antibacterial activity and harmless to the human body. It not only increases the antimicrobial activity of the composition for sterilization of the present invention, but also causes bacteria, microorganisms, fungi, yeast, Algae etc. are removed efficiently. The vitamin B lauryl sulphate is represented by the following formula (1).

Table 1 shows the water solubility of vitamin B lauryl sulphate.

Temperature (℃) Water Solubility of Vitamin B1 Lauryl Sulfate (%) 0 0.01 10 0.01 25 0.21 30 24 40 64 50 100

Lauryl sulfate is usually prepared in powder form due to its easy precipitation and low stability. However, as shown in Table 1, the vitamin B lauryl sulfate has a very low solubility in water, do. Accordingly, in order to prepare vitamin B lauryl sulfate as a liquid preparation, a method of adding acetic acid at a high concentration or ethyl alcohol at a high concentration is known and used. However, since acetic acid and ethyl alcohol generate acetic acid and alcohol odor, , Organic acids are added to make the vitamin B lauryl sulfate soluble in water.

In the present invention, the heavy chain fatty acid is a saturated fatty acid having 8 to 12 carbon atoms. Unlike the long chain fatty acid, the heavy chain fatty acid is rapidly absorbed in the human body and rapidly decomposed and is not accumulated in the body fat. In addition, a heavy chain fatty acid or a heavy chain fatty acid derivative is used in the gastrointestinal infusion improvement technique in the medical field in recent years, and this technique is very important in the field of advanced drug delivery systems.

The heavy chain fatty acids of the present invention may be capric, caprylic, lauric, myristic, palmitic, stearic, oleic, and linoleic, preferably capric or caprylic, It is not limited.

In addition, the composition for sterilization of the present invention can be used for the treatment of enterohemorrhagic Escherichia coli coli O157: H7, E. coli O157: H7), Salmonella spp., Enterococcus faecalis), Staphylococcus aureus (Staphylococcus aureus), methicillin-resistant Staphylococcus aureus (Methicillin-resistant Staphylococcus aureus, MRSA ), pyogenic streptococci (Streptococcus pyogenes), Listeria (Listeria monocytogenes , Escherichia coli , E. coli , Pseudomonas aeruginosa , or Serratia marcescens bacteria, but is not limited thereto.

In one embodiment of the present invention, 30 μl of each of the food-borne microorganisms, enterohemorrhagic Escherichia coli O157: H7, and Salmonella in a tube was added to 3 ml of TSB (Tryptic Soy Broth) and incubated at 37 ° C. for 24 hours. The microbial pellet was washed twice with 0.85% sterile physiological saline, and the same volume of 0.85% sterilized again. The microbial pellet was washed twice with 0.85% sterilized physiological saline, Physiological saline was added and stirred to prepare a broth (see Example 1-1).

In another embodiment of the present invention, standard solutions were prepared by dissolving appropriate concentrations of vitamin B1 lauryl sulfate, capric acid, and caprylic acid in 98% ethanol, respectively (see Example 1-2).

In another embodiment of the present invention, the prepared standard solution is added to sterilized distilled water alone or in combination with sterilized tubes. 0.1 ml of the bacterial solution at a level of 9-10 log CFU / ml is added to 9.9 ml of the treatment solution, C After stirring for 5 minutes in a constant-temperature water bath, the bacterial solution was spread on a flat culture medium, TSA (Tryptic Soy Agar) (see Examples 1-3 and 1-4).

In another embodiment of the present invention, the smoked TSA was cultured in a 37 ° C incubator for 24 hours, and the number of colonies formed in TSA was counted to calculate the number of bacteria. The bacterial concentration was expressed as a log value, , The antimicrobial synergy of vitamin B lauryl sulfate and heavy chain fatty acid was confirmed. As a result, the reduction value of intestinal hemorrhagic Escherichia coli and salmonella was significantly higher than that of vitamin B lauryl sulphate and heavy chain fatty acid alone, (See Example 2). ≪ tb > < TABLE >

In another embodiment of the invention, Enterococcus faecalis ATCC 19433, Staphylococcus aureus ATCC 6538, Methicillin-resistant Staphylococcus aureus (MRSA) ATCC 33591, Streptococcus pyogenes ATCC 14289, Listeria monocytogenes ATCC 7644, E. coli ATCC 11775, Pseudomonas aeruginosa ATCC 15442, And Serratia marcescens ATCC 14756 (see Example 3-1), preparation of vitamin B lauryl sulphate and medium-chain fatty acid standard solution and composition alone or in combination treatment were performed on the above-mentioned food poisoning bacteria (See Example 3-2).

In another embodiment of the present invention, the combination of 1: capric acid 0.1 mM + vitamin B1 lauryl sulfate 0.02%, combination 2: car Lauryl sulphate 0.02%, Vitamin B1 0.02%, Combination ③: Caprylic acid 0.5 mM + Vitamin B1 Lauryl sulfate 0.02% Combination ④: Caprylic acid 1.0 mM + Vitamin B1 Lauryl sulfate 0.02% 4 kinds of combinations were selected and the sterilization effect of the 8 kinds of bacteria was verified. As a result, the combination of 8 kinds of bacteria showed a reduction effect of at least 4 log in all four combinations (see Example 4) ).

Hereinafter, preferred embodiments of the present invention will be described in order to facilitate understanding of the present invention. However, the following examples are provided only for the purpose of easier understanding of the present invention, and the present invention is not limited by the following examples.

Example 1. Preparation of an experiment for verifying the effect of the composition on food poisoning bacteria

1-1. Used strains and culture

Foodborne pathogenic Escherichia coli O157: H7 ( Escherichia coli), a foodborne microorganism that can cause serious food poisoning if contaminated with food coli O157: H7, E. coli O157 : H7) and Salmonella (Salmonella spp was a) selected for the target food poisoning bacteria, E. coli O157:. H7 ( ATCC 35150, 43890, 43895) and S. Typhimurium (ATCC 14028, 19585, DT104 Killercow) were used for the experiments. 30 μl of each strain was inoculated into 3 ml of Tryptic Soy Broth (Difco, Becton Dickinson, Sparks, MD, USA) containing tubes and incubated at 37 ° C. for 24 hours. The cultured bacteria were transferred to a 50 ml plastic tube The supernatant was removed by centrifugation at 3,000 g for 15 minutes using a centrifuge (Centra-CL2, Needham Heights, MA, USA). The supernatant was removed using 0.85% sterile physiological saline The microbial pellet was washed twice, and the same amount of 0.85% sterilized physiological saline was added and stirred to prepare a broth.

1-2. Prepare standard solution of vitamin B ₁ lauryl sulfate and medium chain fatty acid

Vitamin B lauryl sulfate (Daepyung, Korea) was dissolved in 98% ethanol to prepare a standard solution of 1, 2 w / v%. Capric acid (Sigma Chemical Co., St. Louis, MO, USA) was dissolved in 98% ethanol to prepare a standard solution of 10 and 20 mM. Caprylic acid (Sigma Chemical Co., St. Louis, Mo., USA) was dissolved in 98% ethanol to prepare a standard solution of 50, 100 mM.

1-3. Vitamin B1 lauryl sulfate and medium chain fatty acid alone treatment

To the sterilized tube, 0.1 ml of sterilized distilled water, 0.1 ml of the standard solution of vitamin B lauryl sulfate or 0.1 ml of the standard solution of the heavy chain fatty acid (total amount = 9.9 ml) was added to the sterilized tube and 0.1 ml of the bacterial solution at the level of 9-10 log CFU / (Final concentration: 7 to 8 log CFU / ml) to 9.9 ml, treated at 37 ° C for 5 minutes in a constant temperature water bath, and then the mycelial liquid was applied to a Tryptic Soy Agar (Difco, Becton Dickinson, Sparks, (Detection limit: 1 CFU / ml).

1-4. Vitamin B1 Lauryl Sulfate and Combination of Medium Fatty Acid Treatment

To the sterilized tube, 0.1 ml of sterilized distilled water, 0.1 ml of the standard solution of vitamin B lauryl sulfate and 0.1 ml of the heavy chain fatty acid standard solution (total amount = 9.9 ml) were added to the sterilized tube and 0.1 ml of the bacterial solution at the level of 9 to 10 log CFU / (Final concentration: 7 to 8 log CFU / ml) to 9.9 ml, treated at 37 ° C for 5 minutes in a constant temperature water bath, and then the mycelial liquid was applied to a Tryptic Soy Agar (Difco, Becton Dickinson, Sparks, (Detection limit: 1 CFU / ml). Table 2 below shows the w / v% content in the treatment solution of the heavy chain fatty acid.

0.1 mM 0.2 mM 0.5 mM 1.0 mM Capric acid ( capric  acid) 0.0017 w / v% 0.0034 w / v% - - Caprylic acid ( caprylic  acid) - - 0.0072 w / v% 0.0144 w / v%

Example  2. Vitamin B1 Lauryl sulfate and Of heavy chain fatty acids Escherichia coli O157: H7 and  Identification of antimicrobial synergy against Salmonella

)와 처리 후 균수(

)를 토대로 각 조건별 균의 저감화값(

/

)을 산출하였다. 비타민B₁라우릴황산염과 중쇄지방산의 용매로 사용된 에탄올 2%를 대조군으로서 사용하였다. 모든 실험은 3회 이상 반복 수행하였다.In order to confirm the antibiotic synergistic effect of vitamin B lauryl sulfate and medium chain fatty acids (capric acid, caprylic acid), the TSA spilled in Examples 1-3 and 1-4 was cultured in a 37 ° C incubator for 24 hours . The number of bacteria was calculated by counting the number of colonies formed in TSA, and the bacterial concentration was expressed as log value. The same experiment was carried out by inoculating 0.1 ml of the bacterial solution to 9.9 ml of sterilized 0.85% physiological saline to measure the number of inocula. Initial inoculum (

) And after treatment (

) On the basis of the reduction value (

/

). 2% ethanol used as a solvent for vitamin B lauryl sulfate and medium chain fatty acids was used as a control. All experiments were repeated at least three times.

As a result, as shown in FIG. 1, when the vitamin B lauryl sulfate (0.01, 0.02 w / v%) was singly treated, 2 log or more enteric-coated E. coli O157: H7 and Salmonella spp. And no reduction effect of intestinal hemorrhagic Escherichia coli and Salmonella when treated with 0.1 mM capric acid alone in 2% ethanol and heavy chain fatty acids of the control group. However, when combined with vitamin B lauryl sulfate and 0.1 mM capric acid, the reduction effect of enterohemorrhagic Escherichia coli and Salmonella significantly increased to 7 log level. In particular, when 0.1 mM of capric acid and 0.02% of vitamin B lauryl sulfate were administered in combination, the effect of reducing the intestinal hemorrhagic Escherichia coli by 5 log or more was shown, and when the treatment was applied to Salmonella, the effect was reduced by 6 log or more.

In addition, as shown in Fig. 2, when 0.2 mM capric acid was singly treated, it did not show the effect of reducing the intestinal hemorrhagic Escherichia coli and salmonella of 4 log or more. However, 0.2 mM capric acid and 0.02% of vitamin B lauryl sulfate were combined In one case, it was confirmed that both intestinal hemorrhagic Escherichia coli and Salmonella were killed.

In addition, as shown in Fig. 3, when 0.5 mM caprylic acid was singly treated, the effect of reducing the intestinal hemorrhagic Escherichia coli and salmonella was not observed, and 0.5 mM of caprylic acid and 0.01 w / v% of vitamin B lauryl sulphate Combination treatment did not show reduction effect of intestinal hemorrhagic Escherichia coli and salmonella of 4 log or more. However, when 0.5 mM caprylic acid and 0.02 w / v% vitamin B lauryl sulfate were combined, Respectively.

Finally, as shown in FIG. 4, when 1.0 mM caprylic acid alone was treated, it did not show the effect of reducing the intestinal hemorrhagic Escherichia coli and salmonella of 2 log or more. However, 1.0 mM of caprylic acid and vitamin B lauryl sulfate were combined In the case of intestinal hemorrhagic Escherichia coli and salmonella, it was confirmed that more than 7 log kill within 5 minutes.

These results indicate that the antibacterial effect of the combination of the two substances is further increased because the bacterial reduction value is markedly higher during the combination treatment than the value obtained by adding the bacterial lowering value when the vitamin B lauryl sulfate and the heavy chain fatty acid are treated alone Synergistic antimicrobial effect.

Example 3. Experimental preparation for verifying the effect of the composition on various bacteria

3-1. Used strains and culture

In order to confirm the effect of the composition of the present invention on various bacteria in the composition of the combination showing the sterilizing effect in Example 2, Enterococcus faecalis ATCC 19433, Staphylococcus aureus ATCC 6538, Methicillin-resistant Staphylococcus aureus (MRSA) ATCC 33591, Streptococcus pyogenes ATCC 14289, Listeria monocytogenes ATCC 7644, E. coli ATCC 11775, Pseudomonas aeruginosa ATCC 15442, And Serratia marcescens ATCC 14756. The cultivation of the microorganisms and the preparation of the microbial cells were carried out in the same manner as in Example 1-1.

3-2. Vitamin B1 Lauryl Sulfate, Medium Chain Fatty Acid Standard Solution

The preparation of the standard solution and the composition alone or in combination were carried out in the same manner as in Examples 1-2, 1-3, and 1-4.

Example  4. Vitamin B1 in the composition Lauryl sulfate and Of heavy chain fatty acids  Verification of antimicrobial synergy against various bacteria

Combination 1: Capric acid 0.1 mM + Vitamin B1 Lauryl sulfate 0.02%, Combination 2: Carbohydrate 0.1% Lauryl sulphate 0.02%, Vitamin B1 0.02%, Combination ③: Caprylic acid 0.5 mM + Vitamin B1 Lauryl sulfate 0.02% Combination ④: Caprylic acid 1.0 mM + Vitamin B1 Lauryl sulfate 0.02% 'And the effect of various bacteria was verified by selecting 4 combinations in total. The measurement of the number of bacteria and the calculation of the abatement effect were carried out in the same manner as in Example 2 above.

The initial bacterial counts of the eight bacteria among the test results are shown in Table 3, and the degree of the bacterial number reduction is shown in FIG. Treatment results for E. faecalis ATCC 19433, S. aureus ATCC 6538, S. pyogenes ATCC 14289, and P. aeruginosa ATCC 15442 showed 7 log total deaths (ND) for all four combinations. MRSA ATCC 33591, L. monocytogenes ATCC 7644, E. coli ATCC 11775, and S. marcescens Treatment with ATCC 14756 showed a total kill (ND) of 7 log levels in two or three combinations and showed a high reduction effect of at least 4 log in the completely killed group. Therefore, it can be seen that the composition of the present invention exhibits an excellent sterilizing effect on all of the above 8 kinds of target bacteria.

Fungi Initial number of bacteria
(log CFU / ml) Fungi Initial number of bacteria
(log CFU / ml) E. faecalis ATCC 19433 7.2 L. monocytogenes ATCC 7644 6.7 S. aureus ATCC 6538 6.7 E. coli ATCC 11775 7.2 MRSA ATCC 33591 6.9 P. aeruginosa ATCC 15442 7.2 S. pyogenes ATCC 14289 6.9 S. marcescens ATCC 14756 7.7

It will be apparent to those skilled in the art that various modifications and variations can be made in the present invention without departing from the spirit or scope of the invention. There will be. It is therefore to be understood that the above-described embodiments are illustrative in all aspects and not restrictive.

Claims (6)

Vitamin B1 lauryl sulfate and a heavy chain fatty acid as an active ingredient.
The method according to claim 1,
Wherein said heavy chain fatty acid is capric acid or caprylic acid.
The method according to claim 1,
Wherein said vitamin B lauryl sulfate is contained in an amount of 0.005 to 0.05 w / v%.
The method according to claim 1,
Wherein the heavy chain fatty acid is contained in an amount of 0.00085 to 0.02 w / v%.
3. The method of claim 2,
Wherein the capric acid is contained in an amount of 0.00085 to 0.004 w / v%.
3. The method of claim 2,
Wherein the caprylic acid is contained in an amount of 0.005 to 0.02 w / v%.

Images